$ADAG
Adagene Inc. Stock $adag

$adag Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000110465923052043 Filed on April 28, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$5.370M	$9.293M	$8.816M
YoY Change	-39.1%	-8.67%	2160.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.025M	$11.87M	$7.040M
YoY Change	-28.62%	-17.77%	145.29%
% of Gross Profit
Research & Development	$36.19M	$81.34M	$36.64M
YoY Change	-1.22%	19.44%	267.47%
% of Gross Profit
Depreciation & Amortization		$1.146M
YoY Change		1.86%
% of Gross Profit
Operating Expenses	$41.22M	$93.21M	$43.68M
YoY Change	-5.63%	12.93%	240.16%
Operating Profit		-$83.92M
YoY Change		15.97%
Interest Expense	$1.680M	$2.240M	-$381.4K
YoY Change	-540.5%	-351.33%	-40.41%
% of Operating Profit
Other Income/Expense, Net	$1.738M	$2.168M	$956.0K
YoY Change	81.77%	21.9%	198.75%
Pretax Income	-$32.43M	-$79.51M	-$34.29M
YoY Change	-5.42%	11.24%	168.49%
Income Tax	-$99.89K	$459.1K	$1.702M
% Of Pretax Income
Net Earnings	-$32.33M	-$79.97M	-$35.99M
YoY Change	-10.17%	9.28%	181.81%
Net Earnings / Revenue	-602.08%	-860.59%	-408.18%
Basic Earnings Per Share		-$1.48
Diluted Earnings Per Share	-$0.60	-$1.48	-$659.7K
COMMON SHARES
Basic Shares Outstanding	54.07M	54.14M
Diluted Shares Outstanding		54.14M

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$143.8M	$143.8M	$174.4M
YoY Change	-17.57%	-17.57%	132.06%
Cash & Equivalents	$143.8M	$143.8M	$174.4M
Short-Term Investments
Other Short-Term Assets	$4.937M	$4.937M	$4.056M
YoY Change	21.73%	21.73%	6.18%
Inventory
Prepaid Expenses	$1.162M		$1.562M
Receivables	$0.00	$0.00	$3.000M
Other Receivables	$619.4K	$619.4K	$4.507M
Total Short-Term Assets	$149.3M	$149.3M	$186.0M
YoY Change	-19.7%	-19.7%	135.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.975M	$2.975M	$3.488M
YoY Change	-14.7%	-14.7%	68.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$109.6K	$109.6K	$69.28K
YoY Change	58.16%	58.16%	-97.77%
Total Long-Term Assets	$3.084M	$3.084M	$3.557M
YoY Change	-13.28%	-13.28%	-31.07%
TOTAL ASSETS
Total Short-Term Assets	$149.3M	$149.3M	$186.0M
Total Long-Term Assets	$3.084M	$3.084M	$3.557M
Total Assets	$152.4M	$152.4M	$189.5M
YoY Change	-19.58%	-19.58%	124.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.666M	$3.666M	$3.322M
YoY Change	10.37%	10.37%	83.51%
Accrued Expenses	$3.365M	$3.365M	$4.379M
YoY Change	-23.16%	-23.16%	-27.74%
Deferred Revenue	$15.11M		$5.500M
YoY Change	174.68%
Short-Term Debt	$10.77M	$10.77M	$3.121M
YoY Change	245.02%	245.02%	-18.51%
Long-Term Debt Due	$2.850M	$2.850M	$1.376M
YoY Change	107.08%	107.08%	16.64%
Total Short-Term Liabilities	$55.08M	$55.08M	$29.82M
YoY Change	84.7%	84.7%	84.66%
LONG-TERM LIABILITIES
Long-Term Debt	$14.15M	$14.15M	$2.992M
YoY Change	372.84%	372.84%	0.74%
Other Long-Term Liabilities	$82.55K	$82.55K	$94.11K
YoY Change	-12.28%	-12.28%	4.57%
Total Long-Term Liabilities	$14.23M	$14.23M	$3.086M
YoY Change	361.09%	361.09%	0.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$55.08M	$55.08M	$29.82M
Total Long-Term Liabilities	$14.23M	$14.23M	$3.086M
Total Liabilities	$69.31M	$69.31M	$32.95M
YoY Change	110.33%	110.33%	71.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$258.8M		-$178.8M
YoY Change	44.72%
Common Stock	$5.497K		$5.627K
YoY Change	-2.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$83.09M	$83.09M	$156.6M
YoY Change
Total Liabilities & Shareholders Equity	$152.4M	$152.4M	$189.5M
YoY Change	-19.58%	-19.58%	124.91%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$32.33M	-$79.97M	-$35.99M
YoY Change	-10.17%	9.28%	181.81%
Depreciation, Depletion And Amortization		$1.146M
YoY Change		1.86%
Cash From Operating Activities		-$48.61M
YoY Change		11.97%
INVESTING ACTIVITIES
Capital Expenditures		$690.9K
YoY Change		-127.53%
Acquisitions
YoY Change
Other Investing Activities		$4.890K
YoY Change
Cash From Investing Activities		-$686.0K
YoY Change		-72.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		17.82M
YoY Change		-87.74%
NET CHANGE
Cash From Operating Activities		-48.61M
Cash From Investing Activities		-686.0K
Cash From Financing Activities		17.82M
Net Change In Cash		-30.63M
YoY Change		-130.81%
FREE CASH FLOW
Cash From Operating Activities		-$48.61M
Capital Expenditures		$690.9K
Free Cash Flow		-$49.30M
YoY Change		20.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15950698
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50032009
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54135084
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54595667
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54065709
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001818838
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39997
CY2022	dei	Entity Registrant Name EntityRegistrantName	Adagene Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4F, Building C14, No. 218
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Xinghu Street, Suzhou Industrial Park
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Suzhou
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	215123
CY2022	dei	Entity Address Country EntityAddressCountry	CN
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54065709
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1424
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers Zhong Tian LLP
CY2022	dei	Auditor Location AuditorLocation	Shanghai, the People’s Republic of China
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	174391243
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143758678
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3000000
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	4506670
CY2022Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	619432
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4055921
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4937323
CY2021Q4	us-gaap	Assets Current AssetsCurrent	185953834
CY2022Q4	us-gaap	Assets Current AssetsCurrent	149315433
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3487617
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2782963
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191877
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	69275
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	109572
CY2021Q4	us-gaap	Assets Assets	189510726
CY2022Q4	us-gaap	Assets Assets	152399845
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3321615
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3666124
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5500000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15107276
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	10466061
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	19323337
CY2021Q4	adag	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	4379243
CY2022Q4	adag	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	3212809
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1657450
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	3121226
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	10768745
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1376319
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2850128
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151983
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29821914
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55080402
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2991829
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14146541
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53834
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	44163
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	94107
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28718
CY2021Q4	us-gaap	Liabilities Liabilities	32952013
CY2022Q4	us-gaap	Liabilities Liabilities	69309495
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	640000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54595667
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	640000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54065709
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5627
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5497
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	94074
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	619605
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	4
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	336099931
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	342739268
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-93981
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-849305
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178833259
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-258805106
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	156558713
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	83090350
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189510726
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152399845
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	700913
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10175258
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9292724
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33538035
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68099385
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81339540
CY2020	adag	Research And Development Expense Third Parties ResearchAndDevelopmentExpenseThirdParties	23645740
CY2021	adag	Research And Development Expense Third Parties ResearchAndDevelopmentExpenseThirdParties	55020367
CY2022	adag	Research And Development Expense Third Parties ResearchAndDevelopmentExpenseThirdParties	46212077
CY2020	adag	Related Party Transaction Research And Development Expense From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty	9892295
CY2021	adag	Related Party Transaction Research And Development Expense From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty	13079018
CY2022	adag	Related Party Transaction Research And Development Expense From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty	35127463
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10314536
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14439962
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11873867
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-43151658
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-72364089
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-83920683
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	629288
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	76166
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	377501
CY2020	us-gaap	Interest Expense InterestExpense	202165
CY2021	us-gaap	Interest Expense InterestExpense	363762
CY2022	us-gaap	Interest Expense InterestExpense	693323
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	971949
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1778822
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2168388
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-644693
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-603459
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2555325
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42397279
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-71476322
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79512792
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1701613
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	459055
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-42397279
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-73177935
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79971847
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6087
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	257000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-755324
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42403366
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72920935
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-80727171
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-42397279
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-73177935
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79971847
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	248113
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	28553
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42645392
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73206488
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-79971847
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15950698
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50032009
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54135084
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15950698
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50032009
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54135084
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-57008946
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-42397279
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6087
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	140928
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10129541
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	248113
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-89389956
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-73177935
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	257000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	226781
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	416751
CY2021	adag	Common Stock Subscriptions Value CommonStockSubscriptionsValue	381282
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18679658
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	28553
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	154477960
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	147095337
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2361576
CY2021	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	8090
CY2021	adag	Stock Surrendered Value For Repayment Of Promissory Notes StockSurrenderedValueForRepaymentOfPromissoryNotes	-9946
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	156558713
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79971847
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-755324
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	323212
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	391995
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10520282
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	3976681
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	83090350
CY2020	us-gaap	Profit Loss ProfitLoss	-42397279
CY2021	us-gaap	Profit Loss ProfitLoss	-73177935
CY2022	us-gaap	Profit Loss ProfitLoss	-79971847
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	858408
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1125032
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1145995
CY2020	adag	Gain Loss On Sale Of Property Plant Equipment And Operating Lease Right Of Use Asset GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset	327
CY2021	adag	Gain Loss On Sale Of Property Plant Equipment And Operating Lease Right Of Use Asset GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset	18973
CY2022	adag	Gain Loss On Sale Of Property Plant Equipment And Operating Lease Right Of Use Asset GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset	6811
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	10129541
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	18679658
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	10520282
CY2021	adag	Interest Income Expense On Promissory Notes InterestIncomeExpenseOnPromissoryNotes	9946
CY2022	adag	Operating Lease Right Of Use Asset And Interest Of Lease Liabilities Amortization Expense OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense	303535
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-644693
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-603459
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2555325
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-480000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3000000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2337011
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	231287
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	881402
CY2020	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-1300790
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	4374274
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-3887238
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	13292
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	24210
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	40297
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1097261
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1511640
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	344509
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-267842
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4774464
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9607276
CY2020	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	639579
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	7930703
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	8857276
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1243150
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1057491
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-823928
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-280465
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1657450
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1657450
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-44163
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	44163
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	91955
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-29732
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28529720
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43414619
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48611687
CY2020	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	8000000
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	7930
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	4892
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	935199
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2509926
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	690938
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7072731
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2509926
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-686046
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	6083650
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	4386860
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	25830030
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	381282
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	140928
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	231521
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	323212
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	149411950
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	1063670
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	5089717
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	4353588
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	721532
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1595088
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2361576
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3976681
CY2021	adag	Retirement Of Treasury Shares RetirementOfTreasuryShares	8090
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4439376
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	145357142
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17822973
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-364177
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-192352
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	842195
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17381790
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	99240245
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-30632565
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92532788
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75150998
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	174391243
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75150998
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	174391243
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143758678
CY2020	us-gaap	Interest Paid Net InterestPaidNet	202165
CY2021	us-gaap	Interest Paid Net InterestPaidNet	359569
CY2022	us-gaap	Interest Paid Net InterestPaidNet	603680
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2433241
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	313929
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	217227
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	248113
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	28553
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	154477960
CY2020	adag	Payables For Deferred Initial Public Offering Cost PayablesForDeferredInitialPublicOfferingCost	2276183
CY2021	adag	Non Cash Activities Retirement Of Treasury Shares NonCashActivitiesRetirementOfTreasuryShares	1741971
CY2022	adag	Non Cash Activities Retirement Of Treasury Shares NonCashActivitiesRetirementOfTreasuryShares	4596282
CY2021	adag	Surrender Of Common Stock Shares For Repayment Of Promissory Notes SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes	6800856
CY2021Q1	adag	Number Of Shares Surrendered NumberOfSharesSurrendered	491119
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.85
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.85
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group’s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses, and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p>
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	adag	Government Subsidies Received GovernmentSubsidiesReceived	800000
CY2021	adag	Government Subsidies Received GovernmentSubsidiesReceived	1400000
CY2022	adag	Government Subsidies Received GovernmentSubsidiesReceived	2100000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	866028
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	622377
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2223493
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2984251
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2022, the amount of cash and cash equivalents of US$3,650,474 and US$8,617,157 respectively, were held at major financial institutions located in Mainland China, and US$170,740,769 and US$135,141,521,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group’s research and development services were purchased from one supplier group, who collectively accounted for 21.5%,18.5% and 34.1%of the Group’s total research and development services purchases for the years ended December 31, 2020, 2021 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Business and economic risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group believes that changes in any of the following areas could have a material adverse effect on the Group’s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group’s ability to attract employees necessary to support its growth. The Group’s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency exchange rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group’s businesses are transacted in RMB, which is not a freely convertible currency. On January 1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From July 21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 2.29% in the year ended December 31,2021 and appreciation of approximately 9.24% in the year ended December 31, 2022, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group’s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.</p>
CY2021	adag	Percentage Of Depreciation Of Foreign Currency PercentageOfDepreciationOfForeignCurrency	0.0229
CY2022	adag	Percentage Of Depreciation Of Foreign Currency PercentageOfDepreciationOfForeignCurrency	0.0924
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	3000000
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3000000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1562177
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1161910
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1873843
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2970421
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	619901
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	804992
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4055921
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4937323
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8809881
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8692268
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5322264
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5909305
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3487617
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2782963
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	858408
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1125032
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1145995
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	935434
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1647490
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3229794
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1104365
CY2021Q4	us-gaap	Accrued Utilities Current AccruedUtilitiesCurrent	8685
CY2022Q4	us-gaap	Accrued Utilities Current AccruedUtilitiesCurrent	40718
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	62270
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	349039
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	143060
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	71197
CY2021Q4	adag	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	4379243
CY2022Q4	adag	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	3212809
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	3121226
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	10768745
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1376319
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2850128
CY2021Q4	us-gaap	Debt Current DebtCurrent	4497545
CY2022Q4	us-gaap	Debt Current DebtCurrent	13618873
CY2021Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	2991829
CY2022Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	14146541
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2991829
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14146541
CY2021Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	7489374
CY2022Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	27765414
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4497545
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1858619
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	13618873
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1133210
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4124429
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	10022112
CY2021Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	7489374
CY2022Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	27765414
CY2018Q1	adag	Maximum Proceeds Receivable From Exercise Of Warrants MaximumProceedsReceivableFromExerciseOfWarrants	7500000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	154201294
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	154449407
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	154477960
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y5M8D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.65
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.67
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M7D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6328171
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6313373
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.00
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.01
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3694934
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.93
CY2020	adag	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	6.55
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	190000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.70
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	6.91
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3294467
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.75
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.65
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M10D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33410968
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1894119
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.31
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.39
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	233958
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.99
CY2021	adag	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	5.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	145550
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.02
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	7.71
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4809078
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.91
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M4D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2619574
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2640598
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.28
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.13
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	197975
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.08
CY2022	adag	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	6.95
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	964789
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.75
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	7.57
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6286912
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.80
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.16
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	94990
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6286912
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.80
CY2022	adag	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	5.16
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	4239728
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	94990
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1486318
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.87
CY2021	adag	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	7.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	874180
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2070533
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.35
CY2022	adag	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	6.87
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M13D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	55880
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8430085
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	13833856
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11929903
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	23635444
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0068
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0083
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0111
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0192
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0425
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.723
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.734
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.731
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.755
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.742
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.749
CY2020	adag	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum	2.2
CY2020	adag	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum	2.8
CY2021	adag	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum	2.2
CY2021	adag	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum	2.8
CY2022	adag	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum	2.2
CY2022	adag	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum	2.8
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	7147633
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	7951279
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	5286487
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10129541
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18679658
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10520282
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1290009
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	672064
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	367441
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-168846
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1657450
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	503218
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	96804
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-96804
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-52641
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	52641
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	44163
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-44163
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1701613
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	459055
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42397279
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-71476322
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79512792
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10599320
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17869081
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19878198
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	10549985
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	10560029
CY2020	adag	Effective Income Tax Rate Reconciliation Deduction Research And Development Expenses Amount EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount	718979
CY2021	adag	Effective Income Tax Rate Reconciliation Deduction Research And Development Expenses Amount EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount	569016
CY2022	adag	Effective Income Tax Rate Reconciliation Deduction Research And Development Expenses Amount EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount	1724740
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	569575
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1238
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1054
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3695
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	487183
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1790846
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2277418
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4517358
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	291500
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	76127
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-127880
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	10263
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1701613
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	459055
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4949000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8217976
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	391843
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	756197
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	95589
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	94954
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	39166
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	116238
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	29702
CY2022Q4	adag	Deferred Tax Assets Rights Of Use Assets And Lease Liabilities DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities	546
CY2021Q4	adag	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	79
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5083834
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9607456
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5007139
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9524497
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	76695
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	82959
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	120858
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	82959
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	120858
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	82959
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	44163
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2729721
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5007139
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2277418
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4517358
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5007139
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9524497
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	50742841
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-42397279
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-73177935
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79971847
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	248113
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	28553
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42645392
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73206488
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-79971847
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15950698
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50032009
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54135084
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	4506670
CY2022Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	619432
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	10466061
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	19323337
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191877
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151983
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53834
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	283276
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	34729
CY2022	adag	Interest Of Operating Lease Liabilities InterestOfOperatingLeaseLiabilities	20259
CY2022	adag	Operating Lease Rental Expense OperatingLeaseRentalExpense	338264
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	412754
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	255309
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	70367
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	738430
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	157603
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	54823
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	212426
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6609
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	205817
CY2022	adag	Minimum Percentage Of Profits After Tax To Be Transferred To Statutory Reserve MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve	0.10
CY2022	adag	Statutory Reserve Maintenance Required Percentage On Registered Capital StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital	0.50
CY2021Q4	us-gaap	Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries	1860667
CY2022Q4	us-gaap	Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries	1860667
CY2022	adag	After Tax Income Percentage Appropriations AfterTaxIncomePercentageAppropriations	0.10
CY2022Q4	us-gaap	Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries	1860667
CY2022	adag	Threshold Percentage On Restricted Net Assets Of Prc Subsidiaries ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries	0.25

Files In Submission

Name	View Source	Status
0001104659-23-052043-index-headers.html	Edgar Link	pending
0001104659-23-052043-index.html	Edgar Link	pending
0001104659-23-052043.txt	Edgar Link	pending
0001104659-23-052043-xbrl.zip	Edgar Link	pending
adag-20221231.xsd	Edgar Link	pending
adag-20221231x20f.htm	Edgar Link	pending
adag-20221231x20f002.jpg	Edgar Link	pending
adag-20221231x20f003.jpg	Edgar Link	pending
adag-20221231x20f004.jpg	Edgar Link	pending
adag-20221231x20f005.jpg	Edgar Link	pending
adag-20221231x20f006.jpg	Edgar Link	pending
adag-20221231x20f007.jpg	Edgar Link	pending
adag-20221231x20f008.jpg	Edgar Link	pending
adag-20221231x20f009.jpg	Edgar Link	pending
adag-20221231x20f010.jpg	Edgar Link	pending
adag-20221231x20f011.jpg	Edgar Link	pending
adag-20221231x20f012.jpg	Edgar Link	pending
adag-20221231x20f013.jpg	Edgar Link	pending
adag-20221231x20f014.jpg	Edgar Link	pending
adag-20221231x20f015.jpg	Edgar Link	pending
adag-20221231x20f016.jpg	Edgar Link	pending
adag-20221231x20f017.jpg	Edgar Link	pending
adag-20221231x20f018.jpg	Edgar Link	pending
adag-20221231x20f019.jpg	Edgar Link	pending
adag-20221231x20f020.jpg	Edgar Link	pending
adag-20221231x20f021.jpg	Edgar Link	pending
adag-20221231x20f022.jpg	Edgar Link	pending
adag-20221231x20f023.jpg	Edgar Link	pending
adag-20221231x20f024.jpg	Edgar Link	pending
adag-20221231x20f025.jpg	Edgar Link	pending
adag-20221231x20f026.jpg	Edgar Link	pending
adag-20221231x20f029.jpg	Edgar Link	pending
adag-20221231xex12d1.htm	Edgar Link	pending
adag-20221231xex12d2.htm	Edgar Link	pending
adag-20221231xex13d1.htm	Edgar Link	pending
adag-20221231xex13d2.htm	Edgar Link	pending
adag-20221231xex15d1.htm	Edgar Link	pending
adag-20221231xex15d1001.jpg	Edgar Link	pending
adag-20221231xex15d2.htm	Edgar Link	pending
adag-20221231xex15d3.htm	Edgar Link	pending
adag-20221231xex15d3001.jpg	Edgar Link	pending
adag-20221231xex15d4.htm	Edgar Link	pending
adag-20221231xex15d5.htm	Edgar Link	pending
adag-20221231xex2d5.htm	Edgar Link	pending
adag-20221231xex8d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
adag-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
adag-20221231_def.xml	Edgar Link	unprocessable
adag-20221231x20f_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adag-20221231_cal.xml	Edgar Link	unprocessable
adag-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADAG
Adagene Inc. Stock $adag

2022 Q4 Form 20-F Financial Statement

#000110465923052043 Filed on April 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADAG Adagene Inc. Stock $adag

2022 Q4 Form 20-F Financial Statement

#000110465923052043 Filed on April 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADAG
Adagene Inc. Stock $adag